Jean Michel Foidart

About Jean Michel Foidart

Jean Michel Foidart, With an exceptional h-index of 121 and a recent h-index of 46 (since 2020), a distinguished researcher at Université de Liège, specializes in the field of gynecology, cell biology oncology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Prediction of venous thromboembolism risk associated with combined oral contraceptives: an exploratory model

Low thrombin generation in postmenopausal women using estetrol

(059) Estetrol (E4) is a Unique Estrogen With Selective Actions in Tissues Which Are Distinctly Different From the Actions of SERMs

Estetrol: from preclinical to Clinical Pharmacology and advances in the understanding of the molecular mechanism of action

Estetrol: estrogenic activity and coregulator profiling

Effects of E4/DRSP on self-reported physical and emotional premenstrual and menstrual symptoms: Pooled data from two phase 3 clinical trials

Pooled analysis of two multicenter Phase 3 trials of the tolerability and safety of the estetrol/drospirenone combined oral contraceptive

Combined oral contraceptive pill adherence and pregnancy rates

Jean Michel Foidart Information

University

Position

Professeur d'obstétrique et gynécologie

Citations(all)

56450

Citations(since 2020)

11253

Cited By

47756

hIndex(all)

121

hIndex(since 2020)

46

i10Index(all)

547

i10Index(since 2020)

228

Email

University Profile Page

Google Scholar

Jean Michel Foidart Skills & Research Interests

gynecology

cell biology oncology

Top articles of Jean Michel Foidart

Prediction of venous thromboembolism risk associated with combined oral contraceptives: an exploratory model

European Journal of Obstetrics and Gynecology and Reproductive Biology

2024/2/1

Low thrombin generation in postmenopausal women using estetrol

Climacteric

2024/1/19

(059) Estetrol (E4) is a Unique Estrogen With Selective Actions in Tissues Which Are Distinctly Different From the Actions of SERMs

The Journal of Sexual Medicine

2023/6

Estetrol: from preclinical to Clinical Pharmacology and advances in the understanding of the molecular mechanism of action

2023/6

Estetrol: estrogenic activity and coregulator profiling

Endocrine Abstracts

2023/5/2

Effects of E4/DRSP on self-reported physical and emotional premenstrual and menstrual symptoms: Pooled data from two phase 3 clinical trials

Journal of Obstetrics and Gynaecology Canada

2023/5/1

Pooled analysis of two multicenter Phase 3 trials of the tolerability and safety of the estetrol/drospirenone combined oral contraceptive

Journal of Obstetrics and Gynaecology Canada

2023/5/1

Combined oral contraceptive pill adherence and pregnancy rates

Journal of Obstetrics and Gynaecology Canada

2023/5/1

Estetrol (E4) has distinct pharmacokinetic properties and a unique pharmacological profile supported by a tissue-selective mode-of-action

Journal of Obstetrics and Gynaecology Canada

2023/5/1

(068) Low Drug-Drug interaction risk of Estetrol (E4), a Promising New Estrogen for the Treatment of Menopausal Symptoms

The Journal of Sexual Medicine

2023/5

Hormonal therapies and venous thrombosis: considerations for prevention and management—a reappraisal

Research and Practice in Thrombosis and Haemostasis

2023/5

Combined oral contraceptive adherence and pregnancy rates

Obstetrics & Gynecology

2023/5/1

A multicenter, randomized, placebo-controlled study to select the minimum effective dose of estetrol in postmenopausal participants (E4Relief): part 2—vaginal cytology …

Menopause

2023/5/1

The different natural estrogens promote endothelial healing through distinct cell targets

JCI insight

2023/3/3

Impact of estetrol (E4) on hemostasis, metabolism and bone turnover in postmenopausal women

Climacteric

2023/1/2

Role of membrane estrogen receptor alpha on the positive feedback of estrogens on LH secretion

bioRxiv

2023

Hormonal therapies and venous thrombosis: Estrogen matters!

Research and Practice in Thrombosis and Haemostasis

2023/1

Low thrombin generation in users of a contraceptive containing estetrol and drospirenone

The Journal of Clinical Endocrinology & Metabolism

2023/1/1

Estetrol is not a SERM but a NEST and has a specific safety profile on coagulation

Thrombosis Research

2023/12

The benefits of estetrol addition to drospirenone for contraception

AJOG global reports

2023/11/1

Jean Michel Foidart
Jean Michel Foidart

H-Index: 47

Jonathan Douxfils
Jonathan Douxfils

H-Index: 27

See List of Professors in Jean Michel Foidart University(Université de Liège)